Morgan Stanley Sticks to Its Hold Rating for Adaptive Biotechnologies (ADPT)

Retrieved on: 2021-02-26 16:52:30

Tags for this article:

Click the tags to see associated articles and topics

Morgan Stanley Sticks to Its Hold Rating for Adaptive Biotechnologies (ADPT). View article details on hiswai:

Excerpt

Morgan Stanley analyst Tejas Savant maintained a Hold rating on Adaptive Biotechnologies (ADPT) today and set a price target of $60.00.

Article found on: www.smarteranalyst.com